Drugs / BL0006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06247657 | Jan → Oct 2024 | cancer or benign tumor | Shanghai Best-Link Bioscience, LLC | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL0006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06247657 ↗ |
| Route | Intravenous | “Patients will be administered BL0006 via intravenous infusion” NCT06247657 ↗ |